Differences

This shows you the differences between two versions of the page.

--- david_boulware [2023/05/18 01:14]
liam [Education]
+++ david_boulware [2025/04/30 01:29] (current)
liam
@@ Line 9: / Line 9: @@
 ==== Education ====
-Boulware graduated from [[Wabash College]] in 1996 with a Bachelor of Arts in Chemistry.((//Dr. David Boulware ’96/King Distinguished Professor at UMN – Alumni News.// (2011, November 4). Wabash College. http://archive.today/2023.05.17-050444/https://blog.wabash.edu/alumninews/2011/11/04/dr-david-boulware-96king-distinguished-professor-at-umn/)) He later attended the [[Indiana University School of Medicine]], graduating in 2000.((Boulware, D. R. (2021). //Clinical & Translational Research in Cryptococcosis.// Mycoses Study Group Education & Research Consortium. https://web.archive.org/web/20230517231334/https://msgerc.org/resources/Documents/Boulware%20Slides_4.26.pdf))
+Boulware graduated from [[Wabash College]] in 1996 with a Bachelor of Arts in Chemistry.((//Dr. David Boulware ’96/King Distinguished Professor at UMN – Alumni News.// (2011, November 4). Wabash College. http://archive.today/2023.05.17-050444/https://blog.wabash.edu/alumninews/2011/11/04/dr-david-boulware-96king-distinguished-professor-at-umn/)) He was a member of the [[Phi Kappa Psi]] fraternity.((Paige, R. (2020, April 2). //With a Gift for Science, Boulware ’96 Seeks Cure.// Wabash College. http://archive.today/2023.05.17-233333/https://www.wabash.edu/news/story/11580))
+He later attended the [[Indiana University School of Medicine]], graduating in 2000.((Boulware, D. R. (2021). //Clinical & Translational Research in Cryptococcosis.// Mycoses Study Group Education & Research Consortium. https://web.archive.org/web/20230517231334/https://msgerc.org/resources/Documents/Boulware%20Slides_4.26.pdf)) He completed various residencies and fellowships from 2000-2007, receiving a certificate in tropical medicine from the [[Centers for Disease Control and Prevention]] (CDC) in 2006. He completed his Masters in Public Health in 2007.
 ==== Career ====
@@ Line 16: / Line 19: @@
 Boulware joined the faculty of the [[University of Minnesota]] in 2007. He was named to the Lois and Richard King Distinguished Assistant Professorship at UMN in 2011.((//Dr. David Boulware ’96/King Distinguished Professor at UMN – Alumni News.// (2011, November 4). Wabash College. http://archive.today/2023.05.17-050444/https://blog.wabash.edu/alumninews/2011/11/04/dr-david-boulware-96king-distinguished-professor-at-umn/))
-He conducts research on HIV immune reconstitution inflammatory syndrome (IRIS) at the [[Center for Infectious Diseases and Microbiology Translational Research]] (CIDMTR) in collaboration with researchers at the [[Infectious Diseases Institute]] (IDI) in [[uganda:Kampala]], [[Uganda]].((//David R. Boulware, M.D., MPH, DTM&H; - MED - DOM - Infect Diseases Microbiol Trans Research, University of Minnesota.// Center for Infectious Diseases and Microbiology Translational Research. Retrieved June 21, 2010, from https://web.archive.org/web/20100621123616/http://www.cidmtr.umn.edu/investigators/boulware/home.html)) His early efforts were funded by the University of Minnesota's Academic Health Center, [[pharmaceutical_companies:Tibotec]] (which later merged with [[pharmaceutical_companies:Janssen]]) and the [[National Institutes of Health]] (NIH).((Schmickle, S. (2008, November 13). //University of Minnesota doctors battle AIDS in Uganda.// MinnPost. http://archive.today/2010.06.23-113510/http://www.minnpost.com/stories/2008/11/13/4537/university_of_minnesota_doctors_battle_aids_in_uganda))
+Since 2006, Boulware has conducted research through a collaboration between the University of Minnesota and Uganda Hub.((Boulware, D. R. (2021). //Clinical & Translational Research in Cryptococcosis.// Mycoses Study Group Education & Research Consortium. https://web.archive.org/web/20230517231334/https://msgerc.org/resources/Documents/Boulware%20Slides_4.26.pdf)) He has studied cryptococcal meningitis, as well as HIV immune reconstitution inflammatory syndrome (IRIS) at the [[Center for Infectious Diseases and Microbiology Translational Research]] (CIDMTR) in collaboration with researchers at the [[Infectious Diseases Institute]] (IDI) in [[uganda:Kampala]], [[Uganda]].((//David R. Boulware, M.D., MPH, DTM&H; - MED - DOM - Infect Diseases Microbiol Trans Research, University of Minnesota.// Center for Infectious Diseases and Microbiology Translational Research. Retrieved June 21, 2010, from https://web.archive.org/web/20100621123616/http://www.cidmtr.umn.edu/investigators/boulware/home.html)) His early efforts were funded by the University of Minnesota's Academic Health Center, [[pharmaceutical_companies:Tibotec]] (which later merged with [[pharmaceutical_companies:Janssen]]) and the [[National Institutes of Health]] (NIH).((Schmickle, S. (2008, November 13). //University of Minnesota doctors battle AIDS in Uganda.// MinnPost. http://archive.today/2010.06.23-113510/http://www.minnpost.com/stories/2008/11/13/4537/university_of_minnesota_doctors_battle_aids_in_uganda))
 One of Boulware's HIV studies at the IDI, published in December 2017, was featured in the [[Joint United Nations Programme on HIV/AIDS]] (UNAIDS)' August 2018 report titled "[[https://web.archive.org/web/20230508052828/https://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf|Miles to Go]]".((UNAIDS. (2018). //Miles to Go—closing gaps, breaking barriers, righting injustices// (p. 103). Joint United Nations Programme on HIV/AIDS. https://web.archive.org/web/20230508052828/https://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf)) ((Flynn, A., Godwin Anguzu, Mubiru, F., Kiragga, A., Kamya, M. R., Meya, D. B., Boulware, D. R., Kambugu, A., & Castelnuovo, B. (2017). //Socioeconomic position and ten-year survival and virologic outcomes in a Ugandan HIV cohort receiving antiretroviral therapy.// PLOS ONE, 12(12), e0189055–e0189055. https://doi.org/10.1371/journal.pone.0189055)) ((//IDI research manuscript cited in UNAIDS 2018 global report.// Infectious Diseases Institute. Retrieved December 8, 2022, from https://web.archive.org/web/20221208223013/https://idi.mak.ac.ug/idi-research-manuscript/))
@@ Line 35: / Line 38: @@
 On June 3, 2020, the results of Boulware's trial were published in the //[[New England Journal of Medicine]]// (NEJM), finding that "hydroxychloroquine did not prevent illness compatible with [[Covid-19]] or confirmed infection when used as postexposure prophylaxis within 4 days after exposure."((Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., Engen, N. W., Cheng, M. P., LaBar, D., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Zarychanski, R., Kelly, L. E., & Schwartz, I. S. (2020). //A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.// New England Journal of Medicine, 383(6). https://doi.org/10.1056/nejmoa2016638))
+Later in June, Boulware provided commentary to the press about the price of [[remdesivir]], saying that "from the health system perspective, if remdesivir can shorten duration of hospitalization by four days, then the medicine provides a reasonable value."((//Drug company to charge thousands for coronavirus treatment.// (2020, June 29). NBC News; Associated Press. http://archive.today/2020.06.29-144326/https://www.nbcnews.com/health/health-news/remdesivir-coronavirus-gilead-charge-thousands-treatment-u-s-n1232385))
 ===== Activities =====
@@ Line 45: / Line 49: @@
   * [[Doris Duke Charitable Foundation]]
   * [[Fogarty International Center]] (FIC)
+  * [[pharmaceutical_companies:Gilead Sciences]]((MSGERC Headquarters. (2018, October 25). //MSGERC 2018: Cryptococcus: David Boulware.// YouTube. https://web.archive.org/web/20230518194253/https://www.youtube.com/watch?v=QnQ1k4YcCWM))
   * [[pharmaceutical_companies:GlaxoSmithKline]]
   * [[Hennepin Healthcare Research Institute]]
@@ Line 57: / Line 62: @@
   * [[University of Virginia]]
+He has additionally acted as an advisor to [[pharmaceutical_companies:Viamet]] and [[medical_technology_companies:Minnetronix]].((MSGERC Headquarters. (2018, October 25). //MSGERC 2018: Cryptococcus: David Boulware.// YouTube. https://web.archive.org/web/20230518194253/https://www.youtube.com/watch?v=QnQ1k4YcCWM))
 ===== External links =====
+  * [[https://www.linkedin.com/in/davidboulware/|LinkedIn]]
+  * [[https://www.whiteroseintelligence.com/david-boulware/|White Rose Wiki]]
   * [[https://en.wikipedia.org/wiki/David_Boulware|Wikipedia]]